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Diseases caused by insects are frequent in poor countries, leading to epidemic scenarios in urban areas; 
e.g., Dengue, Zika and Chikungunya. For this reason, the development of a safe and efficient topical 
formulation is essential. Ethyl butylacetylaminopropionate (EB) is a mosquito repellent developed by 
Merck, which is used in products for adults, children and especially babies, due to its low allergenic 
potential. The aim of this work was to validate an analytical methodology to quantify EB in a new 
poloxamer-based formulation by high-performance liquid chromatography (HPLC). The quantification 
methodology was performed at 40 ºC using a Kromasil reverse-phase column (C18), with the dimensions 
of 250 x 4.6 mm. The mobile phase was acetonitrile:water (1:1) at a 1.0 mL/min flow-rate. The detector 
wavelength was set at 218 nm to detect EB. The methodology was considered validated since the results 
indicated linearity (R2>0.99), specificity, selectivity, precision and accuracy (active recovery between 
98% and 102%). It also presented limits of detection and quantification of 0.255 µg/mL and 0.849 µg/
mL, respectively. The present study demonstrated the EB vehiculated in poloxamer gel is promising as 
a new insect repellent formulation, since it could be quantified and quality control evaluated. 
Uniterms: Ethyl butylacetylaminopropionate (EB)/quantification. Ethyl butylacetylaminopropionate 
(EB)/topical formulations. Analytical method. Validation. Repellents. Prophylaxis. High Performance 
Liquid Chromatography.
INTRODUCTION
In tropical countries, especially the underdeveloped 
and undeveloped ones, diseases caused by mosquito 
bites are frequent and could cause epidemics (Katz, 
Miller, Heber, 2008). Among diseases spread by 
mosquito bites, one of the most well-known is Dengue, 
however, Chikungunya fever and the Zika virus are being 
thoroughly studied. Currently, researchers all over the 
world are trying to discover if non-specific pathologies 
such as microcephaly could be associated with the Zika 
virus (ZIKV), for example. All the diseases previously 
mentioned have one thing in common: the mosquito Aedes 
aegypti. Therefore, the use of repellent is a recommended 
prophylaxis, which increases the interest in developing 
new long-lasting repellent formulations (Goorhuis et al., 
2016; Moulin et al., 2016; Petersen et al., 2016).
To be considered an ideal repellent, the formulation 
should present the following characteristics: extended 
efficacy against a wide variety of arthropods, no irritation 
potential to the skin after direct application or when 
applied to fabrics that will be in contact with the skin, 
no interaction with packaging, water resistant, has good 
sensorial properties and with no oily residue on the 
skin, nontoxic to humans and the environment and low 
cost stimulating a purchase decision (Frederiksen, Guy, 
Petersson, 2015; Wang et al., 2014; Marcus et al., 2014).
A topical insect repellent formulation must provide 
the retention of the repellent in the upper layer of the 
skin, the epidermis, where the formulation will act, thus 
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preventing its permeation. In addition, it is important that 
the formulation form a homogeneous film on the skin, 
offering resistance to excessive sweating (Frederiksen, 
Guy, Petersson, 2015; Wang et al., 2014; Marcus et al., 
2014).
Essential oil-based formulations are environmentally 
friendly since the active ingredient is collected from plant 
species found in nature. They could also provide protection 
against mosquito bites and have been described in the 
scientific literature as effective and safe (Chattopadhyay et 
al., 2015; Reegan et al., 2014; Tisgratog et al., 2015; Diaz, 
2016). However, the pharmaceutical industry invests large 
amounts of money in safer synthetic repellent ingredients 
since its most famous repellent, diethyltoluamide (DEET), 
is considered by many to be relatively toxic and is not 
recommended for use by pregnant women (Campos et al., 
2016; Wille, Thiermann, Worek, 2011).
One of these non-toxic synthetic repellents is the 
ethyl butylacetylaminopropionate (EB), launched by 
Merck in the global market in 1999. It is an oily, liquid, 
colorless organic substance, volatile under atmospheric 
pressure and at room temperature, slightly soluble in water, 
but soluble in organic solvents. EB action varies according 
to its concentration: 10 wt% in the formulation provides 
efficacy against mosquitoes and its concentration could be 
gradually increased by up to 30 wt%, which will provide 
protection against bees, flies and ticks. Its mechanism of 
action is directly related to its volatility, EB forms a vapor 
barrier that prevents the contact of mosquitoes with the 
skin due to its unpleasant odor, despite being odorless to 
human beings (WHO, 2006). 
Copolymers  of  po ly(e thy lene  oxide) -co-
poly(propylene oxide) could be used to develop topical 
formulations. When it contains 70:30 poly(ethylene oxide) 
(PEO) and poly(propylene oxide) (PPO), respectively, it 
is commercially called Poloxamer 407. This designation 
comes with the two first digits (40) multiplied by 100, 
which represent the variation in the molar weight 
portion of PEO and the third digit (7) when multiplied 
by 10, represents the percentage of the same block in the 
copolymer. Thus, Poloxamer 407 is composed of 70% of 
PEO and consequently 30% of PPO. Since the copolymer 
presents portions with different polarities it could be 
classified as a surfactant, and, for this reason, the hydrogel 
formed is suitable to vehiculate lipophilic molecules, such 
as EB (Devi, Sandhya, Hari, 2013; Almeida et al., 2012; 
Dumortier et al., 2006; Alexandridis, Hatton, 1995).
In this respect, the objective of this study was to 
develop and to validate a methodology to quantify EB 
in repellent formulations. The repellent formulation 
developed in this work aims to better assist the patients 
of the University Pharmacy of UFRJ, namely pregnant 
women and children. Due to its low toxicity, EB is 
recommended for these specific patients. On the other 
hand, DEET has been avoided since it presents a strong 
odor and a potential toxicity. High-performance liquid 
chromatography (HPLC) with UV-vis detection was 
used to quantify EB in the Poloxamer 407 gel formulation 
containing 12.5 and 25% of the repellent.
MATERIAL AND METHODS
Material
EB was purchased from Merck (Germany); the 
preservative used in the formulations was a mixture of 
methylisothiazolinone and phenoxyethanol purchased 
from IPEL (Brazil) and acetonitrile HPLC grade was 
purchased from Tedia (Brazil). For the gel preparation, 
Poloxamer 407 was purchased from Sigma-Aldrich 
(USA).
Equipment
HPLC equipment used was a Gilson with a 321 
model pump, a 152 model ultraviolet-visible detector, a 
7725i model injector (Shimadzu, Canby, OR, USA) with 
a 50 μL loop, a 506C model system interface module, and 
a Gilson Unipoint 3.0 software system controller (Gilson, 
Bedfordshire, UK). A Kromasil reverse-phase column 
(C18) was used with the dimensions of 250 x 4.6 mm and 
5 µm particle size; ultrasound machine Thornton, T14 
model; analytical balance Bioprecisa, FA2104N model 
and spectrophotometer UV / VIS Jasco V-630 model.
Determination of the maximum absorbance 
wavelength 
Firstly, a wavelength scan from 190 to 800 nm 
was performed to determine the maximal absorption 
wavelength of EB (λmáx) using a UV-vis V-630 (Jasco) 
spectrophotometer. A methanol solution of EB in the 
concentration of 300 µg.mL-1 was prepared for the 
analysis.
Analysis by HPLC
The mobile phase was composed of a mixture of 
acetonitrile and water in the ratio of 1:1. As a stationary 
phase a chromatographic C18 column was used with 
dimensions of 250 mm x 4.6 mm and 5 µm particle 
diameter. The volume of each injection was 20 µL, the 
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flow rate of 1 mL.min-1 at a temperature of 40 °C. The 
retention time was 6.3 minutes and EB was detected at 
the wavelength of 218 nm.
Validation of the analytical method
The parameters used for the validation followed 
the recommendations of the ICH (1996) (International 
Council on Harmonization of Technical Requirements 
for Registration of Pharmaceuticals for Human Use) and 
RDC 899 (2003). According to the ICH (1996) guidelines 
and RDC 899 (ANVISA, 2003), the following parameters 
should be assessed: specificity, linearity, interval, 
precision, intermediate precision (inter-day precision), 
accuracy and robustness. Limits of quantification and 
detection were also assessed.
Specificity and selectivity
These parameters have the ability to be evaluated if 
the substances analyzed could be detected in a complex 
mixture, such as the components of a formulation. If 
the selectivity is not assured, linearity, precision and 
accuracy will be compromised. Selectivity was assessed 
by injections of acetonitrile and injections of the placebo 
(the formulation that was developed but without EB).
Linearity
Such a parameter is related to the ability of an 
analytical method to produce results which are directly 
proportional to the concentration of the drug in the 
samples in a determined range of concentration. In 
order to check the linearity, three analytical curves (n=3 
analytical curves) with five different concentrations 
were determined. A stock solution containing 1 mg.ml-1 
of EB was prepared with acetonitrile and water in the 
ratio of 1:1. Then five solutions were prepared in the 
concentrations of 2.5, 5.0, 10.0, 12.5, 15.0 and 20.0 
µg.mL-1. The coefficients of determination (R2) were 
obtained. The linearity results were analyzed by the test 
one-way ANOVA with post test Tukey and significance 
level of α=0.05 (95% of confidence interval). The 
analysis of variance (ANOVA) allowed evaluating the 
linearity of the method and the validity of the linear 
regression. Residue analysis and normal distribution 
were made for evaluation of the homoscedasticity and 
normality, respectively.
Intra-assay precision (repeatability) and inter-assay 
accuracy (intermediate precision)
A measurement is precise if it obtains similar results 
with repeated measurements. For the analysis of intra-
assay precision (intra-day) a triplicate of the analytical 
curve was assessed and the midpoint (10 mg L-1) was 
evaluated 6 times (n= 6 determinations) on the same day.
The inter-assay precision was performed on two 
following days using the same equipment. To analyze the 
inter-assay precision, a triplicate of the analytical curve 
was assessed and the midpoint (10 mg L-1) was evaluated 
6 times (n= 6 determinations) in the two days generating 
twelve replicates (n= 12 determinations). The accuracy 
assessment was performed by the relative standard 
deviation value (RSD) (Equation 1)
  (1)
where RSD is the relative standard deviation, SD is the 
standard deviation. The intra-assay (repeatability) and 
inter-assay (intermediate precision) should not exceed 
5%. These analyses were performed according to the ICH 
“Validation of Analytical Procedures” guidelines (ICH, 
1996).
Robustness
To be robust, an analytical method should show 
reliability with respect to deliberate variations in method 
parameters. Thus, a solution of EB in the concentration of 
10 mg.L-1 was evaluated in sextuplicate being submitted to 
different conditions. Flow, temperature and composition of 
the mobile were varied. The method is considered robust 
when changes are within the limits of acceptable precision 
and accuracy: precision expressed in RSD should be less 
than 5%, and accuracy should remain in the range of ± 5%. 
The robustness results were analyzed by the test one-way 
ANOVA with post test Tukey and significance level of 
α=0.05 (95% of confidence interval).
Detection and quantification limits
The detection limit (DL) is the lowest amount 
of analyte that could be detected in the sample. The 
quantification limit (QL) is the lowest amount of analyte 
in the sample, which could be determined by precision and 
accuracy (Equations 2 and 3) using the data from the three 
curves obtained in the linearity analysis.
  (2)
  (3)
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where SD is the standard deviation of the y intercept of 
three curves and S is the mean of the slope of the three 
curves. 
Accuracy based on the analyte recovery from a 
contaminated placebo
Three amounts of EB (40, 50 and 60 mg) corresponding 
to 80, 100 and 120% of the analyte were added to the vehicle 
(Poloxamer 407 gel with preservative), described in Table 
I. The mobile phase was used to extract EB. An analytical 
curve was set in order to assess the concentration of the EB 
extracted from the contaminated placebo. Accuracy was 
assessed according to Equation 4,
  (4)
where AR% is the accuracy based on the analyte recovery 
from the developed formulation (contaminated placebo), 
AC is the average concentration obtained and TC is the 
theoretical concentration. This study was performed in 
triplicate (n= 3 determinations). Accuracy of the analyte 
should be within the range of 98-102%.
Formulation development
Our research group has developed two formulations 
based on Poloxamer 407 gel, containing 12.5% and 25% of 
EB to be used by children and adults, respectively. Table 
I shows the composition of the developed formulations. 
Firstly, Poloxamer 407 was previously dispersed in cold 
water at 5°C. At low temperatures, water is a good solvent 
for poly(propylene oxide) and poly(ethylene oxide) (Pinto 
et al., 2017). The dispersion was manually mixed and 
refrigerated for 24 h for complete dispersion, hydration, 
and dissolution of Poloxamer 407. The preservative was 
added to the gel with 30 % of Poloxamer 407.
The gel formulations containing 12.5% and 25% 
of EB were prepared by adding EB in the Poloxamer 407 
gel (containing the preservative) under continuous stirring 
with ultra-turrax (at 6,000 RPM) for 10 minutes. During 
the processing, the temperature was kept at 5°C by ice 
bath and the total amount obtained for each formulation 
was 10 g. After being prepared, all formulations were 
stored at 25°C.
EB quantification in the formulations
After the method validation EB concentration 
was determined in both formulations. Six solutions of 
10 µg.mL-1 were prepared for each formulation and an 
analytical curve was also obtained in order to assess the 
amount of EB extracted from the gel formulations. 
Statistical analysis
The experimental results were expressed as mean 
± standard deviation (SD) or relative standard deviation 
(RSD) using Origin Pro 8 (OriginLab, USA) software 
and P value<0.05 was considered statistically significant.
RESULTS AND DISCUSSION
Selectivity and specificity were analyzed by 
injecting of acetonitrile (constituent of the mobile phase), 
gel without EB, EB standard solution in the concentration 
10 µg.mL-1 using the mobile phase (Figure 1A) and EB in 
the concentration of 10 µg.mL-1 obtained after dilution of 
the gel containing 25% of EB in mobile phase (Figure 1B). 
In Figures 1A and 1B, EB presented the same retention 
time of 6.5 minutes, with a peak area corresponding to the 
concentration of 10 µg.mL-1, indicating no interference 
with the mobile phase. There were no peaks of interfering 
materials from the mobile phase and the gel, showing that 
the developed method is selective.
The three analytical curves showed R2 close to 
1, which indicates excellent linearity (Figure 2A). The 
analysis of variance (ANOVA) allowed evaluating 
the linearity of the method and the validity of the 
regression (Table II). The peak area was divided by 
the corresponding concentration, and then the values 
obtained were analyzed by the test one-way ANOVA 
with post test Tukey using a significant level of α=0.05 
(95% of confidence interval). As shown in Table II, the 
value obtained for the F(calculated) is lower than the F(tabulated), 
indicating no significant difference between the values 
obtained (peak area/corresponding concentration) from 
the calibration curves. 
Furthermore, it was observed that the differences 
between the slopes of the analytical curves were not 
TABLE I - Composition of the developed formulation
Ingredient Concentration (%)
EB 12.5 or 25
Phenoxyethanol/Methylisothiazolinone 
(preservative)
0.1
Poloxamer 407 30
Water Qsa) 100
a) Qs: Quantity sufficient.
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significant (p>0.05). The value of F(calculated) (0.649) is lower 
than the F(tabulated) (3.89), indicating no significant difference 
between the slopes of the three analytical curves.
The residue analysis is showed in the Figure 2B. 
The residue analysis exhibited a random pattern, thus, the 
homoscedasticity assumption is satisfied indicating a good 
fit for the linear model. The Figure 2C exhibits the normal 
distribution. The graph is a straight line (Figure 2C), thus, 
the normality assumption is satisfied. Homoscedasticity 
and normality indicated satisfactory adjustment of the 
linear model.
The detection limit (LD) and the quantification limit 
(LQ) were calculated from the three analytical curves 
which are shown in Table III. The values were 0.255 and 
0.849 mg L-1, respectively.
FIGURE 1 - a) Chromatogram showing the peak related to 
EB in a standard solution of 10 µg.mL-1 in mobile phase; 
b) Chromatogram showing the peak related to EB in the 
concentration of 10 µg.mL-1 (also prepared with the mobile 
phase) for the gel formulation containing 25% of EB. No 
interfering materials were detected. 
TABLE II - Analysis of variance (ANOVA) for linearity
Source of variation DF SS MS F calculated P-value* F tabulated
Between groups 2 5081 2540
0.633 0.5293 3.68
Within groups 15 57450 3830
Total 17 62530
DF-degrees of freedom; SS-Sum of squares; MS-Mean square; * p>0.05
FIGURE 2 - Analytical curve (A); residue analysis (B), and 
normal distribution (C).
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For the correct analysis of an analyte the method 
must be precise, providing lower differences among 
data results for the same concentration. Results obtained 
for the intra-assay precision (repeatability) and for the 
inter-assay accuracy (intermediate precision) were 
excellent since, in both, RSD was lower than 5.0% 
(Table III) as recommended by ICH (1996) “Validation 
of Analytical Procedures” guidelines (ICH, 1996). Thus, 
the chromatographic method presented precision.
For the correct analysis of an analyte the method 
must be accurate, there must be a correlation between 
the concentration value obtained and the real or accepted 
concentration value. The results of the intra-assay and 
inter-assay accuracy were also lower 5.0% (Table III). 
Thus, the chromatographic method presented accuracy.
Robustness results are presented in Table IV. 
Precision expressed in RSD should be less than 5%, and 
accuracy should remain in the range of ± 5%. We provide a 
statistical analysis to the robustness results. The robustness 
results, 4 columns with 6 determinations for each column, 
were analyzed by the test one-way ANOVA with post 
test Tukey using the significance level of α=0.05 (95% of 
confidence interval). As shown in Table V, the value for 
F(calculated) is lower than the F(tabulated), indicating no significant 
difference between the robustness values. Changes in flow, 
temperature or mobile phase composition were within the 
range of variation of the precision and accuracy. Thus, the 
chromatographic method presented robustness.
Accuracy based on studies of analyte recovery 
from the contaminated placebo was made by adding three 
different percentages of EB in the vehicle. The average 
recovery ranged from 99.7 to 101.9% (Table VI). 
In addition, the recovery of EB from the developed 
gel formulations was successfully performed and this 
method showed to be exact and suitable for the repellent 
quantification in the new formulations. Table VII 
shows EB was recovered from the gel formulations in 
a percentage of 103.04% (gel with 12.5% of EB) and 
100.30% (gel with 25% of EB). The values were in 
agreement with the percentage limits from 80 to 120% 
TABLE III - Results of the validation parameters: precision, accuracy, detection limit and quantification limit
Validation Parameters Results
Precision intra-assay (Repeatability) (n=6 determinations) RSD= 2.3%
Theoretical concentration (µg.mL-1) 
Concentration obtained (µg.mL-1) 
Accuracy intra-assay (n = 6 determinations)
10 
10.45 
4.5%
Precision inter-assay (n=12 determinations) RSD= 2.5%
Theoretical concentration (µg.mL-1) 
Concentration obtained (µg.mL-1) 
Accuracy inter-assay (n = 12 determinations)
10 
10.46 
4.6%
DL (µg.mL-1) 0.281
QL (µg.mL-1) 0.849
RSD= Relative Standard Deviation; DL= Detection Limit; QL= Quantification limit
TABLE IV - Robustness results
Parameter
Theoretical 
concentration (µg.
mL-1)
Concentration 
obtained 
(µg.mL-1)b
Accuracy (%)b Precisionb
Flux (mL.min-1) 0.9 10 9.72 -2.83 4.31
Flux (mL.min-1) 1.1 10 10.06 0.61 0.79
Temperature (˚C) 40˚C 10 9.74 -2.61 3.23
Mobile phase 40:60 (Water:ACNa) 10 10.21 2.12 2.51
Mean ± SDc 9.93±0.36
RSD (%)c 3.67
a ACN= Acetonitrile; b Mean of 6 determinations; c Mean and RDS of 24 determinations; SD-Standard deviation; RSD-Relative 
Standard deviation (%)
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of the analyte recovery in pharmaceutical formulations 
(ICH, 1996).
CONCLUSION
The methodology was successfully validated and 
applied to insect repellent gel. The chromatographic 
method presented optimal selectivity, linearity higher 
than 0.99, detection and quantification limits lower than 
1 µg.mL-1, relative standard deviation lower than 5% for 
precision, and recovery higher than 90%. Thus, the method 
was suitable for the quantification of EB in the two insect 
repellent gels developed in this work.
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